Edition:
India

Dynavax Technologies Corp (DVAX.OQ)

DVAX.OQ on NASDAQ Stock Exchange Capital Market

15.10USD
13 Jul 2018
Change (% chg)

$-0.15 (-0.98%)
Prev Close
$15.25
Open
$15.30
Day's High
$15.30
Day's Low
$15.05
Volume
105,895
Avg. Vol
334,906
52-wk High
$24.45
52-wk Low
$8.15

Chart for

About

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of... (more)

Overall

Beta: 1.45
Market Cap(Mil.): $1,380.17
Shares Outstanding(Mil.): 59.75
Dividend: --
Yield (%): --

Financials

BRIEF-Dynavax Reports Q1 Loss Per Share Of $0.63

* Q1 EARNINGS PER SHARE VIEW $-0.49 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

09 May 2018

BRIEF-Dynavax Technologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

* DYNAVAX TECHNOLOGIES CORPORATION ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4) Source text for Eikon: Further company coverage:

07 May 2018

BRIEF-Dynavax Provides New Durability Of Response Data For SD-101 In Combination With Keytruda In Melanoma

* DYNAVAX PROVIDES NEW DURABILITY OF RESPONSE DATA FOR SD-101 IN COMBINATION WITH KEYTRUDA (PEMBROLIZUMAB) IN MELANOMA AT THE 2018 AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING

17 Apr 2018

BRIEF-Dynavax Qtrly Loss Per Share $0.45

* DYNAVAX REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS

08 Mar 2018

BRIEF-Dynavax Secures $175 Million In Non-Dilutive Debt Financing

* DYNAVAX SECURES $175 MILLION IN NON-DILUTIVE DEBT FINANCING

20 Feb 2018

Competitors

Earnings vs. Estimates